Neurocrine Biosciences NBIX EV / sales
EV / sales at other companies
Other financials
Where this comes from
Calculated from Neurocrine Biosciences’s reported figures.
Based on the most recent quarter.
The official record: Neurocrine Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Neurocrine Biosciences's ev / sales.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Neurocrine Biosciences's EV / sales?
- Neurocrine Biosciences (NBIX) reported EV / sales of 4.3× in Q1 2026.
- How has Neurocrine Biosciences's EV / sales changed year-over-year?
- Neurocrine Biosciences's EV / sales decreased by 7.9% year-over-year, from 4.7× to 4.3×.
- What is the long-term trend for Neurocrine Biosciences's EV / sales?
- Over 5 years (2020 to 2025), Neurocrine Biosciences's EV / sales has grown at a -10.8% compound annual growth rate (CAGR), from 8.6× to 4.9×.
- What does EV / sales mean?
- What the whole business costs relative to its annual sales.
- How do you interpret EV / sales?
- A fallback valuation gauge for pre-profit or cyclical firms. Like P/S, only comparable across similar-margin businesses, but it accounts for debt and cash unlike P/S.
- How does EV / sales compare across companies?
- Compare within a margin cohort; the debt-and-cash adjustment makes it cleaner than P/S for leveraged firms.